Shupak A, Doweck I, Gordon C R, Spitzer O
Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, Haifa.
Clin Pharmacol Ther. 1994 Jun;55(6):670-80. doi: 10.1038/clpt.1994.84.
Cinnarizine was evaluated for the prevention of seasickness in a laboratory and sea study. The effects of 25 mg cinnarizine on the vestibulo-ocular reflex were investigated in 13 subjects. Significant reduction of the gain in response to sinusoidal oscillations at 0.02, 0.08, and 0.16 Hz (p < 0.05) and increased phase lead at 0.16 Hz (p < 0.01) were observed. The effect of 25 and 50 mg cinnarizine on seasickness severity was examined in 95 subjects during a voyage in rough seas. Seasickness symptoms were improved in 69% of the subjects by 50 mg cinnarizine versus 35% and 31% in the groups receiving 25 mg cinnarizine and placebo (p < 0.05 and p < 0.01, respectively). The percentage of vomiting protection provided by 50 mg cinnarizine was 63% (p < 0.05). We conclude that 50 mg cinnarizine is an effective drug for the prevention of seasickness. The reduction in vestibular sensitivity observed even after administration of 25 mg cinnarizine may explain the potency of cinnarizine in the prevention of seasickness.
在一项实验室研究和海上研究中对桂利嗪预防晕船的效果进行了评估。在13名受试者中研究了25毫克桂利嗪对前庭眼反射的影响。观察到在0.02、0.08和0.16赫兹时，对正弦振荡的增益显著降低（p<0.05），在0.16赫兹时相位超前增加（p<0.01）。在95名受试者于波涛汹涌的海面航行期间，研究了25毫克和50毫克桂利嗪对晕船严重程度的影响。50毫克桂利嗪使69%的受试者晕船症状得到改善，而接受25毫克桂利嗪和安慰剂的组分别为35%和31%（分别为p<0.05和p<0.01）。50毫克桂利嗪提供呕吐防护的百分比为63%（p<0.05）。我们得出结论，50毫克桂利嗪是预防晕船的有效药物。即使服用25毫克桂利嗪后观察到前庭敏感性降低，这也可能解释了桂利嗪预防晕船的效力。
